Patient Care Transitions in COPD: Improving Collaboration Between Inpatient and Outpatient Providers to Reduce Readmissions
|
|
- Erik Hardy
- 6 years ago
- Views:
Transcription
1 Patient Care Transitions in COPD: Improving Collaboration Between Inpatient and Outpatient Providers to Reduce Readmissions Held in conjunction with Hospital Medicine 2017, SHM s Annual Meeting. Provided by Integrity Continuing Education, Inc. Supported by an educational grant from Sunovion Pharmaceuticals, Inc.
2 2 Faculty Panel Brian Carlin, MD, FCCP, MAACVPR, FAARC Sleep Medicine and Lung Health Consultants Pittsburgh, Pennsylvania Senior Staff Physician Pittsburgh Critical Care Associates Pittsburgh, Pennsylvania B. Justin Krawitt, MD Medical Director of Care Management and Clinical Documentation Dartmouth-Hitchcock Medical Center Lebanon, New Hampshire Assistant Professor of Medicine Geisel School of Medicine Dartmouth College Hanover, New Hampshire
3 3 Faculty Disclosures Brian Carlin, MD Consulting fees: Monaghan Medical, Nonin Medical, Philips Respironics, Sunovion Pharmaceuticals, Inc. Speakers Bureau: Monaghan Medical, Philips Respironics, Sunovion Pharmaceuticals, Inc. B. Justin Krawitt, MD Consulting fees: Sunovion Pharmaceuticals, Inc.
4 4 Learning Objectives Describe long-term management strategies that may reduce COPDrelated hospital readmissions Review important comorbidities of COPD as part of a management strategy to reduce readmissions Incorporate physical and cognitive assessments over the course of the inpatient-to-outpatient transition to determine the appropriate device for patients with COPD Improve communication between inpatient and outpatient healthcare providers who manage patients with COPD to better coordinate care transitions
5 5 COPD Readmissions The Current Landscape
6 In-hospital Burden of COPD 1.1 million COPD-related ED visits 1 660,000 hospital discharges 2 $5.7 billion aggregate cost for hospital stays* 3 In-hospital mortality: 4 2.5% for AECOPD-related admissions Up to 28% for patients requiring mechanical ventilation *COPD and bronchiectasis. AECOPD, acute exacerbation of COPD; ED, emergency department. 1. Singh JA, et al. Respir Res. 2016;17:1; 2. Ford ES. Chest. 2015;147(4): ; 3. Pfuntner A, et al. HCUP Statistical Brief #168; 2013; 4. Perera PN, et al. J Chron Obstruct Pulmon Dis. 2012;9:
7 The Hospital Readmissions Reduction Program (HRRP) 2013 Acute MI HF Pneumonia 2015 COPD Total hip arthroplasty Total knee arthroplasty 2017 Aspiration pneumonia Sepsis coded with pneumonia CABG CABG, coronary artery bypass graft; HF, heart failure; MI, myocardial infarction. Available at: 7
8 Hospitals Penalized (%) The Impact of HRRP Percentage of hospitals penalized has risen to 79% over the past 5 years Readmission penalties will rise from $108M (2016) to $528M (2017); fines will range from 1% to 3% of Medicare inpatient payments 78% of 2017 Medicare admissions will be in hospitals receiving penalties Beneficiary readmission rates have continued to drop since 2012, after the HRRP was enacted by the ACA Hospitals with relatively higher shares of low-income beneficiaries and major teaching hospitals are more likely to incur penalties ACA, Affordable Care Act; FY, Fiscal Year. Available at: FY2013 FY2014 FY2015 FY2016 FY2017 8
9 Rate of Readmission (per 100 index stays) Readmission Rates of Four High-volume Conditions ( ) Congestive heart failure COPD Acute myocardial infarction Pneumonia Total index admissions for any cause Year Available at: 9
10 10 Index Hospitalization Stabilization of the Patient with an Exacerbation
11 11 Case Study: Patient Background 65-year-old female with COPD (previously confirmed with spirometry) Presents to ED experiencing an exacerbation for the second time in less than 3 weeks Social history: Widowed in the past year Currently lives with son who travels frequently for business Former smoker with a 40 pack-year history
12 Case Study: Patient Background (Cont d) Medical history: Current diagnosis of GOLD Group B Chronic HF Arthritis Poor vision Mild, but increasing, memory loss over past several months Current medications: Lisinopril Carvedilol Furosemide Nebulized SABA LAMA DPI (admits sporadic use because of difficulty with the device) DPI, dry powder inhaler; GOLD, Global Initiative for Chronic Obstructive Lung Disease; LAMA, long-acting muscarinic antagonist; SABA, short-acting beta 2 -agonist. 12
13 Case Study: Presentation and Exam Presentation: Shortness of breath Cough accompanied by significant sputum Dyspnea: trouble walking across the room Chest tightness Accessory muscle use Difficulty completing sentences Physical exam: Wheezing and decreased breath sounds Temperature: HR: 70, regular rate, no murmurs RR: 24 BP: 130/72 SpO 2 : 86% BP, blood pressure; HR, heart rate; RR, respiration rate; SpO 2, oxygen saturation as measured by pulse oximetry. 13
14 Initial Treatment of an Exacerbation Bronchodilator therapy Increase doses/frequency of SABA therapy Combine SABAs with anticholinergics Use spacers or air-driven nebulizers Corticosteroids Antibiotics O 2 therapy Adjunctive therapies Noninvasive or invasive mechanical therapies Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Available at: 14
15 5-day Course of Corticosteroids Preferred for COPD Exacerbations Patients Without Exacerbation (%) GOLD Stage 3-4 FEV 1 ~31% predicted Randomized to 5 days or 14 days of prednisone (40 mg) Short-term group (5 days) Conventional group (14 days) 5-day regimen noninferior to 14-day regimen Average hospital stays 1 day shorter with 5-day regimen Time From Inclusion (days) FEV 1, forced expiratory volume in 1 second. Leuppi JD, et al. JAMA. 2013;309(21):
16 Discussion 16
17 17 Case Study: Hospital Admission The patient is admitted to the hospital based upon the following factors: Exacerbation history Age Concerns about home care environment
18 Guiding Principles I: Stabilization of the Patient with an Exacerbation 18 Management should be targeted at minimizing the negative impact of the current exacerbation and preventing the occurrence of future exacerbations and disease progression.
19 Inpatient Management 19
20 Comorbidities Associated with Increased Risk of Disease Progression and Future Exacerbations CHF OSTEOPOROSIS SKELETAL MUSCLE WEAKNESS COPD PROGRESSION AND FUTURE EXACERBATION LUNG CANCER ANXIETY DEPRESSION CHF, congestive heart failure. 20
21 Impact of Comorbidities on Risk for 30-day COPD-related Readmission Early COPD-related Rehospitalization Favors No COPD-related Favors COPD-related Yes No Odds Ratio Rehospitalization Rehospitalization (n=174) (n=3438) (95% CI) P value Anxiety 44 (25.3) 561 (16.3) 1.68 (1.17, 2.41).005 Asthma 71 (40.8) 1036 (30.1) 1.57 (1.14, 2.16).006 Congestive heart failure 45 (25.9) 811 (23.6) 1.19 (0.84, 1.70).322 Diabetes 73 (42.0) 1142 (33.2) 1.45 (1.06, 1.97).019 Depression 31 (17.8) 511 (14.9) 1.18 (0.79, 1.77).422 Dyspnea 122 (70.1) 2011 (58.5) 1.63 (1.17, 2.27).004 Hypertension 116 (66.7) 2131 (62.0) 1.27 (0.92, 1.75).150 Hypoxia 23 (13.2) 284 (8.3) 1.67 (1.06, 2.63).028 Ischemic heart disease 76 (43.7) 1115 (32.4) 1.73 (1.26, 2.38) <.001 Osteoporosis 15 (8.6) 328 (9.5) 1.03 (0.59, 1.79).915 Pneumonia: -30 to -1 days 14 (8.0) 174 (5.1) 1.62 (0.92, 2.86) to -1 days 15 (8.6) 190 (5.5) 1.65 (0.95, 2.85) to -91 days 16 (9.2) 175 (5.1) 1.84 (1.08, 3.16) to -181 days 18 (10.3) 223 (6.5) 1.66 (1.00, 2.76) to -271 days 24 (13.8) 321 (9.3) 1.53 (0.98, 2.39) to -1 days 54 (31.0) 701 (20.4) 1.75 (1.25, 2.43).001 Pulmonary vascular disease 15 (8.6) 283 (8.2) 1.06, 0.61, 1.82).843 Stroke 16 (9.2) 366 (10.6) 0.91 (0.53, 1.53).710 Charlson Index (weighted) 2.1 ± ± (0.89, 1.12).980 CI, confidence interval. Roberts MH, et al. BMC Pulm Med. 2016;16(1): Odds Ratio (95% CI) 21
22 GOLD 2017: The Redefined ABCD Assessment Tool Spirometrically confirmed COPD Assessment of airflow limitation Assessment of symptoms/ risk of exacerbations Post-bronchodilator FEV 1 /FVC <0.7 GOLD FEV 1 (% predicted) <30 Exacerbation History 2 or 1 leading to hospital admission 0 or 1 (not leading to hospital admission) CAT, COPD Assessment Test; FVC, forced vital capacity; mmrc, modified Medical Research Council Dyspnea Scale. GOLD 2017 Update. Available at: C A mmrc 0 1 CAT <10 Symptoms D B mmrc 2 CAT 10 22
23 Treatment Recommendations by GOLD Grade LAMA + LABA GROUP C LABA + ICS Consider roflumilast* GROUP D Further exacerbation(s) Consider macrolide Further exacerbation(s) LAMA GROUP A Continue, stop, or try alternative bronchodilator class LAMA + LABA + ICS Persistent symptoms/further Further exacerbation(s) exacerbation(s) LAMA LAMA + LABA LABA + ICS GROUP B LAMA + LABA Evaluate effect Persistent symptoms A bronchodilator LABA or LAMA *If FEV 1 is <50% predicted and patient has chronic bronchitis; In former smokers. GOLD 2017 Update. Available at: 23
24 Pharmacologic Options Bronchodilators Anti-Inflammatory Short-Acting Long-Acting Inhaled Anticholinergic (SAMA) Ipratropium β 2 -Agonists (SABA) Albuterol Levalbuterol Metaproterenol Pirbuterol SAMA + SABA Ipratropium + albuterol Anticholinergic (LAMA) Tiotropium Aclidinium Umeclidinium β 2 -Agonists (LABA) Salmeterol, or 2 -Agonists Formoterol, (LABA) or Arformoterol, Salmeterol, or Indacaterol, or Formoterol, Olodaterol or Arformoterol, or Indacaterol (ultra), or Olodaterol LAMA + LABA Tiotropium + olodaterol LAMA LABA Umeclidinium + vilanterol Tiotropium + olodaterol Glycopyrrolate + indacaterol Umeclidinium vilanterol Xanthine Derivative: Theophylline Xanthine Derivative: Theophylline ICS + LABA Fluticasone + salmeterol Budesonide + formoterol Fluticasone + vilanterol
25 25 Therapies on the Horizon Type Agent Delivery LAMA Glycopyrronium bromide Nebulizer MDI LABA/LAMA Aclidinium + formoterol DPI LABA/LAMA/ICS Glycopyrronium + formoterol + budesonide MDI
26 Discussion 26
27 Association Between Disease Control and One or More Critical Inhaler Errors* Odds Ratio Hospital Admissions ED Visits Antimicrobial Courses Corticosteroid Courses *Data includes asthma and COPD patient populations. Dekhuijzen PNR, et al. Patient Prefer Adherence. 2016;10: ; Melani AS, et al. Respir Med. 2011;105(6):
28 28 Common Inhaler Devices DPI MDI SMI Nebulizer
29 Assessments to Aid in Device Selection Cognitive Any test for higher-level cognitive function Failure indicates MDI or DPI may be inappropriate Physical Validated teach-back methods for specific devices Check for inspiratory flow (eg, In-Check DIAL) Available at: 29
30 Overcoming Cognitive and Physical Limitations Cognitive Physical Limitation Unable to coordinate breathing with device requirements Unable to remember instructions for device actuation Unable to keep track of doses Unable to generate adequate PIFR Impaired manual dexterity Pain or weakness from neuromuscular disease Potential Strategy Spacer, SMI, nebulizer Device with fewer steps, nebulizer Device with a dose counter SMI, nebulizer Nebulizer Nebulizer PIFR, peak inspiratory flow rate. Wise RA, et al. Chron Obstruct Pulmon Dis. 2017;4(1):13. Dhand R, et al. J Chron Obstruct Pulmon Dis. 2012;9(1):58-72; Nobles J, et al. Consult Pharm. 2014;29(11):
31 31 Case Study: In-hospital Care Patient is doing well with corticosteroid and antibiotic treatment Corticosteroids and antibiotics are continued Maintenance bronchodilator therapy is initiated
32 Hospital Stays for Exacerbations of COPD Following Initiation of LAMA Hospital Stay (± SD, days) *P< January February March Jan-Mar Combined * Early addition of tiotropium to a respiratory therapist-directed bronchodilator protocol for patients hospitalized for an exacerbation reduced hospital stays and costs with no safety concerns. SD, standard deviation. Drescher GS, et al. Respir Care. 2008;53(12):
33 Readmission Rate (%) Odds of Readmission 31% Lower When Nebulized LABA Initiated in Hospital Neb-SABA Arformoterol P= Overall, significantly lower (8.7% vs 11.9%) 30-day readmissions with arformoterol P= P= P= Minor Moderate Major Extreme Severity of Illness Bollu V, et al. Int J Chron Obstruct Pulmon Dis. 2013;8:
34 DPI Handling Errors Are More Frequent with Greater COPD Severity Error Rate (%) No COPD Mild Moderate Severe Severity of COPD Lareau SC, et al. J Am Acad Nurse Pract. 2012;24(2): Wieshammer S, et al. Respiration. 2008;75(1):
35 Inpatient Portable Spirometry Can Be Used to Identify Patients with COPD Obstructed on inpatient spirometry Obstructed on outpatient spirometry Unobstructed on outpatient spirometry Total 45 (75%) 15 (25%) 60 Unobstructed on inpatient spirometry 4 (28.6%) 10 (71.4%) 14 Total Inpatient portable spirometry during AECOPD can predict airflow obstruction that persists after recovery. Note: Inpatient spirometry was a poor predictor of follow-up severity of obstruction. Loh C, et al. Am J Respir Crit Care Med. 2016;193:A
36 Guiding Principles II: Considerations for Management of the Stable Inpatient 36 The diagnosis of COPD should be confirmed and the patient should be comprehensively assessed (ie, for extent of airflow limitation, symptom severity, and risk for future exacerbations) In addition, maintenance therapy regimens should be reevaluated, adjusted, and initiated during the hospital stay to insure that treatment is appropriate given the physiological and behavioral characteristics of the patient
37 37 Transitions of Care Opportunities to Reduce Readmissions
38 38 Case Study: Patient Discharge Patient is symptomatically improved for 24 hours and is ready to return home Issues revealed by comprehensive assessment of the patient s psychosocial situation over the hospital stay are considered: Ability to obtain medications Access to transport Health literacy Insurance coverage of the patient s treatments
39 Discussion 39
40 Preparing Patients With COPD for Safe Transitions of Care Upon admission At discharge Postdischarge Initiate processes to reduce readmission risk factors Initiate processes to reduce readmission risk factors Educate patients and and caregivers caregivers in a patient-centered in a patient-centered manner manner Address key patient and caregiver concerns Address key patients and caregiver concerns Provide discharge instructions without without medical medical jargon using jargon teach using back teach back Communicate with with outpatient HCPs HCPs about about hospital hospital stay and stay ongoing and care ongoing care Provide a a complete discharge summary summary to outpatient to outpatient HCPs HCPs Complete medication reconciliation Coordinate outpatient outpatient follow-up follow-up visits visits Check in with patients for early warning signs of an adverse event Provide patient resources needed to handle events if disease worsens Promptly send completed discharge summaries to outpatient HCPs Connect patients to community resources Available at: Innovation/Implementation_Toolkit/COPD/Best_Practices/transitions_pall.aspx. 40
41 Pulmonary Rehabilitation Programs in the US Available at: 41
42 The Pittsburgh Regional Health Initiative: A Case Study in Reducing Hospital Readmissions The Perfect Discharge Bundle Root cause analysis 30 minutes of patient education Pharmacist medication review Discharge action plan Note to physician within 72 hours following discharge Phone call to patient within 72 hours following discharge The Primary Care Resource Center: A New Model for Complex Patients. Available at: 42
43 Guiding Principles III: Care of the Patient at Discharge At discharge, the goals of care during and after the next 30 days should be discussed with patients Patients should receive education on device training, therapeutic expectations, medication adherence, and nonpharmacologic interventions Follow-up consisting of a home care visit or a call from the transition care team, and an appointment with a PCP should be scheduled PCP, primary care provider. 43
44 44 Audience Response Question Approximately what percentage of PCPs in the United States report being notified when a patient is discharged from the hospital or seen in an ED? A. 10% B. 30% C. 50% 8 0% 0% 0% A. B. C.
45 % of Cases Communication Between Inpatient and Outpatient Healthcare Providers 80 Notified of ED visit Notified of hospital discharge NET NZ UK NOR US CAN SWIZ GER AUS SWE In the US, only one-third of PCPs reported being notified when a patient is discharged from the hospital or seen in an ED Commonwealth Fund International Health Policy Survey of Primary Care Physicians. Available at: 45
46 Discussion 46
47 Improving Communication Between Inpatient and Outpatient HCPs Employment of multiple modes of communication Reliable, standardized discharge documentation Consistent, concise, complete medication & treatment plans Rattray NA, et al. Jt Comm J Qual Patient Saf. 2017;43(3):
48 Importance of Follow-up After Hospitalization for an Exacerbation An outpatient visit within 1 month after admission resulted in fewer ED visits (14%) and 30-day readmissions (9%) 1 30-day readmission was 10 times more likely for patients not attending primary care follow-up within 4 weeks postdischarge 2 Not attending a follow-up visit within 30 days was associated with an increased risk of rehospitalization within 90 days of discharge (OR, 2.91; 95% CI, ) 3 1. Sharma G, et al. Arch Intern Med. 2010;170(18): ; 2. Misky GJ, et al. J Hosp Med. 2010;5(7): ; 3. Gavish R, et al. Chest. 2015;148(2):
49 49 Case Study: 2-week Follow-up Visit Patient reports improved adherence to her therapeutic regimen Symptoms have significantly improved
50 Guiding Principles IV: Preventing 30-Day Readmissions 50 The goals during the transition of care are to ensure alignment between inpatient and outpatient healthcare providers, and the return of the patient to a safe home environment in which home care providers are equipped to successfully implement the plan of care, monitor health status, and prevent the need for hospital readmission.
51 Additional Resources SHM Project BOOST Project RED (Re-Engineered Discharge) COPD Foundation The Primary Care Resource Center: A New Model for Complex Patients (PRHI) PRHI, Pittsburgh Regional Health Initiative; SHM, Society of Hospital Medicine. 51
52 52 Summary Exacerbations of COPD represent a significant health and economic burden in the hospital setting In-hospital care provides an important opportunity to improve long-term COPD management via confirmation of diagnosis and optimization of maintenance therapy during inpatient treatment and following discharge Individualized discharge and transitional care plans that address specific behavioral, physical, and environmental barriers to care can prevent hospital readmissions
53 Thank You! 53
THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable
THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. COPD in the United States Third leading cause
More informationCOPD: A Renewed Focus. Disclosures
COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss
More informationCOPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms
COPD: Preventable and Treatable Christopher H. Fanta, M.D. Partners Asthma Center Pulmonary and Critical Care Division Brigham and Women s Hospital Harvard Medical School Lecture Outline I. Diagnosis and
More informationUp in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More informationCOPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor
COPD Update Plus New and Improved Products for Inhaled Therapy Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose concerning possible financial
More informationCOPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
More informationCOPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health
COPD: Treatment Update Barry Make, MD Professor of Medicine National Jewish Health Disclosures Advisory board, consultant, multi-center trial, research funding, Data Safety Monitoring Board (DSMB), or
More informationDisclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:
Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict
More informationVA/DoD Clinical Practice Guideline Management of COPD Pocket Guide
VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide MODULE A: MAAGEMET OF COPD 1 2 Patient with suspected or confirmed COPD presents to primary care [ A ] See sidebar A Perform brief clinical
More informationFact. Objectives 1/6/2016. Reducing Hospital Readmissions for Chronic Obstructive Pulmonary Disease (COPD)
Reducing Hospital Readmissions for Chronic Obstructive Pulmonary Disease (COPD) Jin S. Oh, PharmD Larkin Community Hospital January 10, 2016 Fact COPD is the third leading cause of death in the United
More informationChronic Obstructive Pulmonary Disease (COPD) Clinical Guideline
Chronic Obstructive Pulmonary Disease (COPD) Clinical These clinical guidelines are designed to assist clinicians by providing an analytical framework for the evaluation and treatment of patients. They
More information11/27/18. Challenges in Pulmonary and Critical Care: COPD So Much is New! Faculty. Disclosures
Challenges in Pulmonary and Critical Care: 2018 COPD So Much is New! 1 Faculty Anas Hadeh, MD, FCCP Director, Pulmonary and Critical Care Medicine Fellowship Program Affiliate Assistant Professor of Clinical
More informationChronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC
Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC I have no financial disclosures Definition COPD is a preventable and treatable disease
More informationCOPD: From Hospital to Home October 5, 2015 Derek Linderman, MD Associate Professor COPD Center Pulmonary Nodule Clinic
COPD: From Hospital to Home October 5, 2015 Derek Linderman, MD Associate Professor COPD Center Pulmonary Nodule Clinic Learning Objectives Know the adverse effects of COPD exacerbations Know mainstays
More informationSurveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.
Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma
More informationCOPD: GOLD guidelines Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS
COPD: GOLD guidelines 2017 Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS Introduction The Global Initiative for Chronic Obstructive Lung Disease (GOLD) program was
More informationPharmacotherapy for COPD
10/3/2017 Topics to be covered Pharmacotherapy for chronic treatment Pharmacotherapy for COPD Dr. W C Yu 3rd September 2017 Commonly used drugs Guidelines for their use Inhaled corticosteroids (ICS) in
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD)
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) Zahava Picado, PharmD PGY1 Pharmacy Practice Resident Central Texas Veterans Healthcare System Temple, TX October
More informationCARE OF THE ADULT COPD PATIENT
CARE OF THE ADULT COPD PATIENT Target Audience: The target audience for this clinical guideline is all MultiCare providers and staff including those associated with our Clinically Integrated Network. The
More informationGINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017
GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and
More informationChronic obstructive pulmonary disease
0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find
More informationFaculty Affiliation. Faculty Disclosures. Maintenance Therapy for Patients with COPD in Longterm Care Settings
Maintenance Therapy for Patients with COPD in Longterm Care Settings Sponsored by Integrity Continuing Education, Inc. Supported Practitioner s by Edge an is educational a registered service grant from
More informationCLINICAL PATHWAY. Acute Medicine. Chronic Obstructive Pulmonary Disease
CLINICAL PATHWAY Acute Medicine Chronic Obstructive Pulmonary Disease Chronic Obstructive Pulmonary Disease Table of Contents (tap to jump to page) INTRODUCTION 1 Scope of this Pathway 1 Pathway Contacts
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More information2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters
GOLD Objectives To provide a non biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD. To highlight short term and long term treatment objectives organized
More informationAt-A-Glance Outpatient Management Reference for Chronic Obstructive Pulmonary Disease (COPD)
At-A-Glance Outpatient Management Reference f Chronic Obstructive Pulmonary Disease (COPD) BASED ON THE GLOBAL STRATEGY FOR DIAGNOSIS, MANAGEMENT AND PREVENTION OF COPD GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE
More informationSupplementary materials
Supplementary materials Table S1 Patient comorbidities by diagnosis Total Asthma n (%) 5348 (148.4) COPD n (%) 4563 (143.4) ACOS n (%) 469 (197.9) No other comorbidities 95 (26.4) 614 (19.3) 27 (11.4)
More informationWirral COPD Prescribing Guidelines
Wirral COPD Prescribing Guidelines (To be read in conjunction with the Wirral COPD Supplementary Information) STEP 1: Assess symptoms COPD Assessment Test (CAT) [Link for CAT-test Online] is a patient-completed
More informationPresented by UIC College of Nursing
Presented by UIC College of Nursing Describe COPD. Identify red flags for a COPD exacerbation. Identify COPD triggers or risk factors. Differentiate between long-acting inhalers and emergency use inhalers.
More informationChronic Obstructive Pulmonary Disease 1/18/2018
Presented by UIC College of Nursing Describe COPD. Identify red flags for a COPD exacerbation. Identify COPD triggers or risk factors. Differentiate between long acting inhalers and emergency use inhalers.
More informationChronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines
Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines Where appropriate the following should be offered before commencing inhaled treatment: Offer treatment and support to stop smoking. Smoking
More informationPeak Expiratory Flow Rate (PEFR) for ED Management of Acute Asthma Exacerbation
Peak Expiratory Flow Rate (PEFR) for ED Management of Acute Asthma Exacerbation PI: Brian Driver, MD Checklist Reviewed Inclusion and Exclusion Criteria Confirm pertinent exclusion criteria with PMP Engage
More informationJOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES
JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam
More informationIf you require this document in another format such as Braille, large print, audio or another language please contact the Trusts Communications Team
MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULTS Summary statement: How does the document support patient care? Staff/stakeholders involved in development: Job titles only Division:
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationBreaking Down Barriers to Pulmonary Therapies: Patient Education, Teach Back, and More
Breaking Down Barriers to Pulmonary Therapies: Patient Education, Teach Back, and More Char Raley, RRT Brandon Johnson, PharmD, BCPS Pulmonary and Critical Care Symposium June 12 th, 2015 We have had no
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationChoosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital
Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies
More informationCOPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.
1 Definition of COPD: COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis. Airflow obstruction may be accompanied by airway hyper-responsiveness
More informationCOPD/Asthma. Prudence Twigg, AGNP
COPD/Asthma Prudence Twigg, AGNP COPD/Asthma Qualifying Diagnosis Known diagnosis of COPD/asthma or CXR showing COPD with hyperinflated lungs and no infiltrates + two or more: Wheezing, SOB, increased
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) October 26 th, 2018 Zahava Picado, PharmD PGY1 Pharmacy Resident Central Texas Veterans Healthcare System Zahava.Picado@va.gov
More informationRespiratory Therapists as COPD Educators
Respiratory Therapists as COPD Educators Becky Skinner, RRT-ACCS, CHT, MBA 38 th Annual Respiratory Care Seminar October 2018 1 Disclosure Statement I have no financial relationship with any manufacturer
More informationII: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical
Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%
More informationFaculty Presenters. Leonard M. Fromer, MD Executive Medical Director Group Practice Forum Los Angeles, California
Faculty Presenters Leonard M. Fromer, MD Executive Medical Director Group Practice Forum Los Angeles, California Frank C. Sciurba, MD Associate Professor of Medicine Medical Director, Pulmonary Physiology
More informationACO Impact on Transitions of Care: Witnessing the Improved Value of Re Engineering Communication at All Points of Care
ACO Impact on Transitions of Care: Witnessing the Improved Value of Re Engineering Communication at All Points of Care Christopher B Cooper, MD Professor of Medicine and Physiology David Geffen School
More informationCHARM Guidelines for the diagnosis and
\ CHARM Guidelines for the diagnosis and management of COPD City and Hackney CCG Homerton University Hospital NHS Foundation Trust Written by: Miss Hetal Dhruve, Specialist Pharmacist Respiratory Medicine,
More informationGuideline for the Diagnosis and Management of COPD
Guideline for the Diagnosis and Management of COPD Introduction Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking. It is characterized by progressive, partially
More informationTHE COPD PRESCRIBING TOOL
THE COPD PRESCRIBING TOOL Revised edition, 2017 www.bpac.org.nz/copd CLASSIFICATION The COPD prescribing tool This tool provides pharmacological treatment options for patients with COPD based on their
More informationTurning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital
Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe
More informationNews on Evidence-Based Care Fourth Quarter 2013 Volume 5 Issue 4
SPECIAL EDITION: COPD CME AVAILABLE! News on Evidence-Based Care Fourth Quarter 2013 Volume 5 Issue 4 Update on Chronic Obstructive Lung Disease (COPD) 2013 During 2013, the Institute for Evidence-Based
More informationManagement of Acute Exacerbations of COPD
MiCMRC Educational Webinar Management of Acute Exacerbations of COPD August 22, 2018 MiCMRC Educational Webinar Management of Acute Exacerbations of COPD Expert Presenter: Catherine A. Meldrum PhD RN MS
More informationCOPD Diagnosis, Management and Program
COPD Diagnosis, Management and Program RYAN MARTIN, MD NEBRASKA PULMONARY SPECIALTIES Initial diagnosis Setting matters: Inpatient. Usually sicker, oftentimes avoiding healthcare. Outpatient. Often seeking
More informationTest Your Inhaler Knowledge
A Breath of Fresh Air: Updates in COPD Management Jennifer Austin Szwak, PharmD, BCPS, DPLA University of Chicago Medicine The speaker has nothing to disclose Abbreviations COPD: Chronic obstructive pulmonary
More informationPrescribing guidelines: Management of COPD in Primary Care
Prescribing guidelines: Management of COPD in Primary Care Establish diagnosis of COPD in patients 35 years with appropriate symptoms with history, examination and spirometry (FEV1/FVC ratio < 70%) Establish
More informationWhat s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university
What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent
More informationSTRIVERDI RESPIMAT (olodaterol hcl) aerosol
STRIVERDI RESPIMAT (olodaterol hcl) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More information2017 GOLD Report. Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017
2017 GOLD Report Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017 Lauren Munro; BSc(Pharm) Amanda Burns; BSc(Pharm) Pharmacy Residents The Moncton Hospital Objectives Explain
More informationOptimizing COPD Management in Primary Care
Clinical Updates for Nurse Practitioners and Physician Assistants: 2018 Optimizing COPD Management in Primary Care Sandra Adams, MD, MS Professor, Division of Pulmonary Diseases and Critical Care Medicine
More informationManagement of COPD Updates and Evidence
Management of COPD Updates and Evidence Providence Alaska Medical Center PGY1 Pharmacy Practice Residents Ann-Chee Cheng, PharmD Kaite Kammers, PharmD http://www.fpnotebook.com/_media/lungxsgraybb962.gif
More informationAdvances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015
Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Chronic obstructive pulmonary disease (COPD) COPD in Hong
More informationChronic Obstructive Pulmonary Disease Guidelines and updates
Chronic Obstructive Pulmonary Disease Guidelines and updates October 20, 2018 Saratoga Springs, NY COPD (Chronic obstructive pulmonary disease) is a major cause of mortality and morbidity in the United
More informationAddress Comorbidities
Greater Manchester COPD Management Plan Non-pharmacological management for ALL patients Smoking Cessation Annual Flu Vaccination Pulmonary Rehabilitation Increase daily activity Inhaler Technique Measure
More informationImproving Outcomes in COPD
Neil MacIntyre MD Duke University Durham NC Current treatment guidelines f COPD focus Barriers to providing optimal treatment Diagnosis of COPD EXPOSURE TO RISK FACTORS AND/ OR SYMPTOMS sputum cough dyspnea
More informationTRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder
TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationSyllabi/Slides for this program are a supplement to the live CME session and are not intended for other purposes.
10:50-11:50am Case Studies in Pulmonary Medicine for the Primary Care Clinician SPEAKERS Timothy J. Scialla, MD Common Shortcuts/Common Misperceptions Smoking + Dyspnea = COPD Hospitalization for cough
More informationHQO s Episode of Care for Chronic Obstructive Pulmonary Disease
HQO s Episode of Care for Chronic Obstructive Pulmonary Disease Dr. Chaim Bell, MD PhD FRCPC Ontario Hospital Association Webcast October 23, 2013 Objectives 1. Describe the rationale and methodology for
More informationCOPD. Breathing Made Easier
COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationChronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease CareOregon Pharmacy Abridged sample of presentation content Home Equipment Pathophysiology Exacerbations Guidelines Lifestyle Modification Medication Management Sample
More informationThe Acute & Maintenance Treatment of Asthma via Aerosolized Medications
The Acute & Maintenance Treatment of Asthma via Aerosolized Medications Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Associate Professor and Chairman Department of Respiratory Therapy Objectives Define Asthma.
More informationApril 10 th, Bond Street, Toronto ON, M5B 1W8
Comprehensive Research Plan: Inhaled long-acting muscarinic antagonists (LAMAs; long-acting anticholinergics) for the treatment of chronic obstructive pulmonary disease (COPD) April 10 th, 2014 30 Bond
More informationWhat is COPD? COPD Pharmacotherapy. COPD Mortality Is Increasing
COPD Pharmacotherapy Chronic Bronchitis What is COPD? 75% 17.5% Emphysema Laura C. Feemster, MD, MS Assistant Professor University of Washington Division of Pulmonary & Critical Care April 23,2015 COPD
More informationCourse Handouts & Disclosure
COPD: Disease Trajectory and Hospice Eligibility Terri L. Maxwell PhD, APRN VP, Strategic Initiatives Weatherbee Resources Hospice Education Network Course Handouts & Disclosure To download presentation
More informationAlgorithm for the use of inhaled therapies in COPD
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More information2/12/2015. ASTHMA & COPD The Yin &Yang. Asthma General Information. Asthma General Information
ASTHMA & COPD The Yin &Yang Arizona State Association of Physician Assistants March 6, 2015 Sedona, Arizona Randy D. Danielsen, PhD, PA-C, DFAAPA Dean & Professor A.T. Still University Asthma General Information
More informationAlgorithm for the use of inhaled therapies in COPD Version 2 May 2017
Algorithm for the use of inhaled therapies in COPD This document has been revised by the Berkshire West Respiratory Network to support clinicians in selecting the most appropriate, cost effective treatments
More informationThree better than 1 or 2?
Three better than 1 or 2? DISCLOSURE Pam McLean-Veysey, Team Leader Drug Evaluation Unit DEU funded by the Drug Evaluation Alliance of NS. (DEANS). DEU prepares Drug Evaluation Reports for the Atlantic
More informationObjectives. Advances in Managing COPD Patients
4:45 5:30pm Advances in Managing Patients SPEAKER Nicola Hanania, MD, FCCP, FRCP, FACP Presenter Disclosure Information The following relationships exist related to this presentation: Nicola Hanania, MD,
More informationAECOPD: Management and Prevention
Neil MacIntyre MD Duke University Medical Center Durham NC Professor P.J. Barnes, MD, National Heart and Lung Institute, London UK Professor Peter J. Barnes, MD National Heart and Lung Institute, London
More informationAsthma: Evaluate and Improve Your Practice
Potential Barriers and Suggested Ideas for Change Key Activity: Initial assessment and management Rationale: The history and physical examination obtained from the patient and family interviews form the
More informationCOPD Robert Schilz DO, PhD Pulmonary, Critical Care and Sleep Medicine University Hospitals Case Medical Center
COPD 2018 GOLD 2017 Report Global Initiative for Chronic Obstructive Lung D isease COPYRIGHTED MATERIAL- DO NOT COPY OR DISTRIBUTE GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF CHRONIC
More informationDisclosure Statement. Epidemiological Data
EVALUATION OF THE MEDICATION UTILIZATION OF COPD PATIENTS AT THE MIAMI VA HEALTHCARE SYSTEM Simone Edgerton, PharmD. PGY 1 Pharmacy Resident Miami VA Healthcare System Miami, Florida Simone.edgerton2@va.gov
More informationA COPD medication delivery device option: an overview of the NEOHALER
A COPD medication delivery device option: an overview of the NEOHALER 2017 Sunovion Pharmaceuticals Inc. All rights reserved 9/17 RESP019-17 Indication and Boxed Warning INDICATION ARCAPTA NEOHALER (indacaterol)
More informationCOPD exacerbation. Chiara Maruggi, PGY2
COPD exacerbation Chiara Maruggi, PGY2 Learning objectives At the end of this lecture students will be able to: 1) Critically assess patients for COPD and design a management plan. 2) Develop a step-wise
More informationCME/CE QUIZ CME/CE QUESTIONS
CME/CE QUIZ CME/CE QUESTIONS Continuing Medical Education Accreditation The University of Cincinnati College of Medicine designates this educational activity for a maximum of 2 Category 1 credits toward
More informationMedicines Management of Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) (Chronic & Acute) Guidelines for Primary Care Guideline Authors: Shaneez Dhanji (Wandsworth CCG) Samantha Prigmore (St George s Hospital)
More informationOptimizing COPD Management in Primary Care
Clinical Updates for Nurse Practitioners and Physician Assistants: 2018 Optimizing COPD Management in Primary Care Sandra Adams, MD, MS Professor, Division of Pulmonary Diseases and Critical Care Medicine
More informationCOPD Prescribing Guidelines
Cannock Chase Clinical Commissioning Group South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group Stafford and Surrounds Clinical Commissioning Group East Staffordshire Clinical Commissioning
More informationDecramer 2014 a &b [21]
Buhl 2015 [19] Celli 2014 [20] Decramer 2014 a &b [21] D Urzo 2014 [22] Maleki-Yazdi 2014 [23] Inclusion criteria: Diagnosis of chronic obstructive pulmonary disease; 40 years of age or older; Relatively
More informationChanging Landscapes in COPD New Zealand Respiratory Conference
Changing Landscapes in COPD New Zealand Respiratory Conference Dr Robert Young BMedSc MBChB DPhil (Oxon) FRACP FRCP Associate Professor Consultant Physician Changing Landscapes in COPD: Summary 1. Overview
More informationNHS Dumfries & Galloway Triple therapy in COPD patients over 16 years
Title of Project: NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years 1 Reason for the review Respiratory prescribing is long term and can be costly. Appropriate choice and use of inhaled
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP 3 Main Categories Inhaled Respiratory Drugs Binds to beta-2 receptors Relaxation of smooth muscles in the lung
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationBackground. Background. Background 3/14/2014. Conflict of Interest Statement:
Platform Presentations Comparison of zolpidem to other drugs associated with falls in hospitalized patients Ed Rainville, MSPharm. Conflict of Interest Statement: The speaker has no conflict of interest
More informationCOPD Update. Muhammad Talha Khan MD. COPD Exacerbations. COPD Clinical Importance. COPD Pathophysiology. Overview/Objectives
Overview/Objectives COPD Update Muhammad Talha Khan MD Pulmonologist St Croix Regional Medical Center, St Croix Falls, WI. Overview of COPD and disease impact Classification of COPD Severity Treatment
More informationLearning Objectives. Why Target Rehospitalization in COPD? Agenda. Case: 78-year-old Smoker with Progressive SOB and Cough, Sputum for One Week
Learning Objectives Utilize guideline-concordant maintenance pharmacotherapy, along with appropriate nonpharmacologic strategies, to reduce exacerbation risk and improve quality of life in patients with
More informationumeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline
umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline 07 November 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationPEDIATRIC ACUTE ASTHMA SCORE (P.A.A.S.) GUIDELINES. >97% 94% to 96% 91%-93% <90% Moderate to severe expiratory wheeze
Inclusion: Children experiencing acute asthma exacerbation 24 months to 18 years of age with a diagnosis of asthma Patients with a previous history of asthma (Consider differential diagnosis for infants
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Calverley P M A, Anzueto A R, Carter K, et
More information